vs
Beneficient（BENF）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Beneficient的1.0倍（$19.6M vs $18.7M），Beneficient净利率更高（106.7% vs -177.4%，领先284.1%），Beneficient同比增速更快（322.5% vs -11.5%）
Beneficient是一家专注于另类资产流动性解决方案的金融服务企业，为私募股权、对冲基金份额、实物资产等非流动资产持有者提供定制化服务，客户主要涵盖北美地区的机构投资者、高净值人士及家族办公室。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
BENF vs LAB — 直观对比
营收规模更大
LAB
是对方的1.0倍
$18.7M
营收增速更快
BENF
高出334.0%
-11.5%
净利率更高
BENF
高出284.1%
-177.4%
损益表 — Q3 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $19.6M |
| 净利润 | $19.9M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 21.1% | -168.5% |
| 净利率 | 106.7% | -177.4% |
| 营收同比 | 322.5% | -11.5% |
| 净利润同比 | 330.5% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BENFLAB
| Q4 25 | $18.7M | — | ||
| Q3 25 | $-2.8M | $19.6M | ||
| Q2 25 | $-12.6M | $21.8M | ||
| Q1 25 | $-31.0M | $40.8M | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $8.6M | $22.1M | ||
| Q2 24 | $10.0M | $22.5M | ||
| Q1 24 | — | $45.5M |
净利润BENFLAB
| Q4 25 | $19.9M | — | ||
| Q3 25 | $-17.9M | $-34.7M | ||
| Q2 25 | $-92.6M | $-33.5M | ||
| Q1 25 | $-44.6M | $-26.0M | ||
| Q4 24 | $-8.6M | — | ||
| Q3 24 | $9.7M | $-26.9M | ||
| Q2 24 | $44.3M | $-45.7M | ||
| Q1 24 | — | $-32.2M |
毛利率BENFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率BENFLAB
| Q4 25 | 21.1% | — | ||
| Q3 25 | 646.5% | -168.5% | ||
| Q2 25 | 734.0% | -118.1% | ||
| Q1 25 | 146.3% | -80.8% | ||
| Q4 24 | -215.3% | — | ||
| Q3 24 | -160.2% | -120.9% | ||
| Q2 24 | — | -134.5% | ||
| Q1 24 | — | -132.2% |
净利率BENFLAB
| Q4 25 | 106.7% | — | ||
| Q3 25 | 648.1% | -177.4% | ||
| Q2 25 | 734.0% | -153.7% | ||
| Q1 25 | 144.1% | -63.8% | ||
| Q4 24 | -195.5% | — | ||
| Q3 24 | 113.9% | -122.0% | ||
| Q2 24 | 441.1% | -203.3% | ||
| Q1 24 | — | -70.6% |
每股收益（稀释后）BENFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.9M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-128.6M | $399.7M |
| 总资产 | $337.9M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BENFLAB
| Q4 25 | $7.9M | — | ||
| Q3 25 | $4.9M | $129.4M | ||
| Q2 25 | $7.6M | $158.6M | ||
| Q1 25 | $1.3M | $150.9M | ||
| Q4 24 | $4.1M | — | ||
| Q3 24 | $4.5M | $210.6M | ||
| Q2 24 | $4.4M | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务BENFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益BENFLAB
| Q4 25 | $-128.6M | — | ||
| Q3 25 | $-142.8M | $399.7M | ||
| Q2 25 | $-120.4M | $424.5M | ||
| Q1 25 | $-34.9M | $454.6M | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $-13.2M | $489.3M | ||
| Q2 24 | $-148.3M | $510.3M | ||
| Q1 24 | — | $577.3M |
总资产BENFLAB
| Q4 25 | $337.9M | — | ||
| Q3 25 | $316.2M | $539.6M | ||
| Q2 25 | $334.5M | $557.0M | ||
| Q1 25 | $354.9M | $579.6M | ||
| Q4 24 | $400.0M | — | ||
| Q3 24 | $368.8M | $681.5M | ||
| Q2 24 | $361.3M | $708.7M | ||
| Q1 24 | — | $777.7M |
负债/权益比BENFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.4M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | 0.0% | 4.5% |
| 现金转化率经营现金流/净利润 | -0.47× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流BENFLAB
| Q4 25 | $-9.4M | — | ||
| Q3 25 | $-14.5M | $-22.2M | ||
| Q2 25 | $-10.8M | $-20.7M | ||
| Q1 25 | $-37.7M | $-30.3M | ||
| Q4 24 | $-10.0M | — | ||
| Q3 24 | $-8.6M | $-27.9M | ||
| Q2 24 | $-10.6M | $-39.0M | ||
| Q1 24 | — | $-62.5M |
自由现金流BENFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | $-10.9M | $-22.6M | ||
| Q1 25 | $-38.8M | $-35.3M | ||
| Q4 24 | $-10.0M | — | ||
| Q3 24 | $-8.9M | $-30.1M | ||
| Q2 24 | $-11.3M | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率BENFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | 86.6% | -103.6% | ||
| Q1 25 | 125.3% | -86.6% | ||
| Q4 24 | -227.2% | — | ||
| Q3 24 | -103.7% | -136.4% | ||
| Q2 24 | -112.6% | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度BENFLAB
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | -0.8% | 8.7% | ||
| Q1 25 | -3.5% | 12.4% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 3.1% | 10.2% | ||
| Q2 24 | 6.6% | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率BENFLAB
| Q4 25 | -0.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.88× | — | ||
| Q2 24 | -0.24× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BENF
| Ben Liquidity | $8.2M | 44% |
| Other | $7.6M | 41% |
| Ben Custody | $2.9M | 16% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
